Microbiome and colorectal cancer: A review of the past, present, and future

2021 ◽  
Vol 37 ◽  
pp. 101560
Author(s):  
Michael S. Johns ◽  
Nicholas J. Petrelli
Keyword(s):  
Colorectal Cancer ◽  
The Past

scholarly journals The crucial roles of N6-methyladenosine (m6A) modification in the carcinogenesis and progression of colorectal cancer

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Zhihao Fang ◽  
Yiqiu Hu ◽  
Jinhui Hu ◽  
Yanqin Huang ◽  
Shu Zheng ◽  
...  
Keyword(s):  
Gene Expression ◽  
Colorectal Cancer ◽  
Nuclear Export ◽  
Messenger Rna ◽  
Regulatory Proteins ◽  
Biological Processes ◽  
The Past ◽  
Common Cancer ◽  
Potential Applications ◽  
Regulated Gene Expression

AbstractAs the predominant modification in RNA, N6-methyladenosine (m6A) has attracted increasing attention in the past few years since it plays vital roles in many biological processes. This chemical modification is dynamic, reversible and regulated by several methyltransferases, demethylases and proteins that recognize m6A modification. M6A modification exists in messenger RNA and affects their splicing, nuclear export, stability, decay, and translation, thereby modulating gene expression. Besides, the existence of m6A in noncoding RNAs (ncRNAs) could also directly or indirectly regulated gene expression. Colorectal cancer (CRC) is a common cancer around the world and of high mortality. Increasing evidence have shown that the changes of m6A level and the dysregulation of m6A regulatory proteins have been implicated in CRC carcinogenesis and progression. However, the underlying regulation laws of m6A modification to CRC remain elusive and better understanding of these mechanisms will benefit the diagnosis and therapy. In the present review, the latest studies about the dysregulation of m6A and its regulators in CRC have been summarized. We will focus on the crucial roles of m6A modification in the carcinogenesis and development of CRC. Moreover, we will also discuss the potential applications of m6A modification in CRC diagnosis and therapeutics.

Su1932 - Despite Surveillance and Increased use of Biologics and Immunosuppressives Colorectal Cancer Detection in IBD Patients Remains Unchanged over the Past 10 Years

2018 ◽  
Vol 154 (6) ◽  
pp. S-637
Author(s):  
Uday N. Shivaji ◽  
Samuel C. Smith ◽  
Rahul Hejmadi ◽  
Subrata Ghosh ◽  
Marietta Iacucci
Keyword(s):  
Colorectal Cancer ◽  
Cancer Detection ◽  
The Past

scholarly journals Adjuvant treatment of colorectal cancer

2002 ◽  
Vol 49 (2) ◽  
pp. 15-18
Author(s):  
J.A. Wils
Keyword(s):  
Colorectal Cancer ◽  
Adjuvant Treatment ◽  
Large Scale ◽  
New Drugs ◽  
Morbidity And Mortality ◽  
The Past ◽  
The Future ◽  
The Usa

Colorectal cancer is a leading cause of morbidity and mortality, with approximately 300,000 new cases and 200,000 related deaths in Europe and the USA each year. Adjuvant treatment of colorectal cancer is now widely accepted and can reduce mortality with approximately 10%. This can be considered as one of the major achievements in oncology from the past decade. Current results will be discussed and strategies for the future will be outlined, including on-going or planned large-scale trials with new drugs and approaches.

Is more better than less? Caveats from bevacizumab and cetuximab combination in colorectal cancer

2011 ◽  
Vol 3 (1) ◽  
pp. 1
Author(s):  
Camillo Porta
Keyword(s):  
Colorectal Cancer ◽  
Life Expectancy ◽  
Cancer Patients ◽  
Advanced Colorectal Cancer ◽  
The Past ◽  
Colorectal Cancer Patients ◽  
Better Than ◽  
Made In

In the past few years, impressing improvements have been made in the treatment of advanced colorectal cancer. Following decades of modest achievements, in which it was just a matter of dose and schedule for 5-FU and leucovorin—the only treatment then available—first, the development of irinotecan and oxaliplatin, and then the use of the two biologicals, bevacizumab and cetuximab, have dramatically improved the life expectancy of our colorectal cancer patients...

scholarly journals Molecular Targets for the Treatment of Metastatic Colorectal Cancer

Cancers ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 2350
Author(s):  
Romain Cohen ◽  
Thomas Pudlarz ◽  
Jean-François Delattre ◽  
Raphaël Colle ◽  
Thierry André
Keyword(s):  
Colorectal Cancer ◽  
Molecular Targets ◽  
Predictive Biomarkers ◽  
Therapeutic Strategies ◽  
Her2 Amplification ◽  
Liquid Biopsies ◽  
Braf Mutations ◽  
Genetic Characteristics ◽  
New Developments ◽  
The Past

Over the past years, colorectal cancer (CRC) was subtyped according to its molecular and genetic characteristics, allowing the development of therapeutic strategies, based on predictive biomarkers. Biomarkers such as microsatellite instability (MSI), RAS and BRAF mutations, HER2 amplification or NTRK fusions represent major tools for personalized therapeutic strategies. Moreover, the routine implementation of molecular predictive tests provides new perspectives and challenges for the therapeutic management of CRC patients, such as liquid biopsies and the reintroduction of anti-EGFR monoclonal antibodies. In this review, we summarize the current landscape of targeted therapies for metastatic CRC patients, with a focus on new developments for EGFR blockade and emerging biomarkers (MSI, HER2, NTRK).

Rightward shift of colorectal cancer in Italy during the past three decades

2004 ◽  
Vol 39 (8) ◽  
pp. 783-786 ◽  
Author(s):  
C. Cucino ◽  
F. Parente ◽  
G. Bianchi Porro
Keyword(s):  
Colorectal Cancer ◽  
Rightward Shift ◽  
The Past

scholarly journals Complementary medicine use in US adults with a history of colorectal cancer: a nationally representative survey

2020 ◽  
Vol 29 (1) ◽  
pp. 271-278
Author(s):  
Charlene HL Wong ◽  
Tobias Sundberg ◽  
Vincent CH Chung ◽  
Petra Voiss ◽  
Holger Cramer
Keyword(s):  
Colorectal Cancer ◽  
Cancer Survivors ◽  
Cancer Patients ◽  
Complementary Medicine ◽  
Medicine Use ◽  
The Past ◽  
The Us ◽  
History Of ◽  
Mind Body Medicine ◽  
Colorectal Cancer Patients

Abstract Background In the USA, colorectal cancer is among the top diagnosed cancers. The current study specifically targets the US adult population that have a history of colorectal cancer. Methods We used the 2017 National Health Interview Survey (NHIS) to investigate the prevalence and predictors of colorectal cancer survivors using complementary medicine in the past 12 months in a representative sample of the US population (N = 26,742). We descriptively analyzed the 12-month prevalence of any complementary medicine use separately for individuals with a prior diagnosis of colorectal cancer and those without. Using chi-squared tests and backward stepwise multiple logistic regression analyses, we identified predictors of complementary medicine use in the past 12 months. Results A weighted total of 1,501,481 US adults (0.6%) had a history of colorectal cancer. More individuals without (weighted n = 76,550,503; 31.2%) than those with a history of colorectal cancer (weighted n = 410,086; 27.3%) had used complementary medicine. The most commonly used complementary medicine among colorectal cancer patients was mind-body medicine, followed by chiropractic. A higher prevalence of complementary medicine use was associated with being female, higher educated and/or living in the US Midwest or South. Conclusions In this study, over one fourth of the US colorectal cancer survivors had used complementary medicine. Mind-body medicine was found to be the most commonly used. With evidence supporting the effectiveness and safety of mind-body medicine use among colorectal cancer patients, promoting the use of evidence-based mind-body medicine for colorectal cancer management could be considered.

Early Onset Colorectal Cancer: Changes in Presentation and Survival Over the Past 20 Years

2012 ◽  
Vol 107 ◽  
pp. S563
Author(s):  
Matthew Chin ◽  
Fouzia Khan ◽  
Gurjot Singh ◽  
Albert Lin ◽  
Ahmad Kamal
Keyword(s):  
Colorectal Cancer ◽  
Early Onset ◽  
The Past ◽  
Early Onset Colorectal Cancer

Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next

2012 ◽  
pp. 223-230
Author(s):  
Thierry André ◽  
Bert H. O'Neil ◽  
Jeffrey A. Meyerhardt
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Clinical Trials ◽  
Complementary Therapies ◽  
Stage Iii ◽  
Stage Iii Colon Cancer ◽  
The Past ◽  
What Works ◽  
Metastatic Setting ◽  
Diet And Exercise

Overview: Adjuvant treatment for patients with stage III colon cancer, one of the most common malignancies, is an important issue in oncology. The use of adjuvant chemotherapy in this setting has undoubtedly improved prognosis. This article describes the development of adjuvant therapy and progress in the past decade as well as failures in multiple agents that have demonstrated efficacy in the metastatic setting. Finally, the current clinical trials will be reviewed, as well as complementary therapies including diet and exercise for survivors of colorectal cancer.

MicroRNAs for Diagnosis and Treatment of Colorectal Cancer

2020 ◽  
Vol 20 ◽  
Author(s):  
Haitao Mei ◽  
Yugang Wen
Keyword(s):  
Colorectal Cancer ◽  
Disease Free Survival ◽  
Diagnosis And Treatment ◽  
High Morbidity ◽  
Circulating Micrornas ◽  
Free Survival ◽  
The Past ◽  
Common Cancer ◽  
Disease Free

: Colorectal cancer (CRC) is the third most common cancer worldwide, with high morbidity and mortality rates. The diagnosis and treatment of CRC have the most significant value for disease-free survival. Early diagnosis and early surgical resection are generally considered to be the most effective ways to reduce CRC mortality. In the past few years, many researchers have focused on the role of microRNAs in different tumors, making the functions of microRNAs gradually clear. The present study reviews the role of microRNAs in the diagnosis and treatment of colorectal cancer. Compared with the usual diagnosis methods and biomarker, circulating microRNAs can be promising new effective biomarkers for CRCdiagnosis and treatment.

Sign in / Sign up

Export Citation Format

Share Document